IZRL - ETF AI Analysis
Top Page
ARK Israel Innovative Technology ETF (IZRL)
Rating:53Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown generally strong recent returns over the past month and quarter, indicating positive momentum.
Innovative Technology Focus
Many top holdings are in technology and health care, giving investors exposure to innovative companies with growth potential.
Balanced U.S. and Israeli Exposure
The fund spreads its investments between U.S. and Israeli companies, reducing reliance on a single market.
Negative Factors
Moderate Expense Ratio
The fund’s fees are not extremely high but are above what many broad, low-cost index ETFs charge, slightly reducing net returns.
Sector Concentration in Technology
A large portion of the ETF is invested in technology-related companies, which can make the fund more sensitive to swings in that sector.
Mixed Performance Among Top Holdings
While several top positions have performed strongly, a few have shown weak or negative results, which can drag on overall performance.
IZRL vs. SPDR S&P 500 ETF (SPY)
AUM134.53M
RegionMiddle East & Africa
Expense Ratio0.49%
Beta0.88
IssuerARK
Inception DateDec 05, 2017
Dividend Yield2.67%
Asset ClassEquity
Index TrackedARK Israeli Innovation (USD)(TR)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume10,853
30 Day Avg. Volume11,124
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IZRL Summary
IZRL is the ARK Israel Innovative Technology ETF, which follows the ARK Israeli Innovation index and focuses on Israel’s fast-growing tech scene. It holds a mix of technology, healthcare, and communication companies, including names like Silicom and Camtek, that work in areas such as cybersecurity, artificial intelligence, and biotech. An investor might choose IZRL to get diversified exposure to many innovative Israeli companies in a single investment, aiming for long-term growth from new technologies. However, because it is heavily focused on tech and innovation, its price can go up and down sharply with changes in the market and the tech sector.
How much will it cost me?The ARK Israel Innovative Technology ETF (IZRL) has an expense ratio of 0.49%, which means you’ll pay $4.90 per year for every $1,000 you invest. This expense ratio is slightly higher than average because the fund is actively managed and focuses on a specific niche, requiring more research and management effort.
What would affect this ETF?The ARK Israel Innovative Technology ETF (IZRL) could benefit from global demand for advanced technologies like artificial intelligence and cybersecurity, areas where Israeli companies excel. However, geopolitical tensions in the Middle East or regulatory changes affecting tech companies could pose risks to its performance. Economic conditions, such as interest rate hikes, may also impact growth-focused sectors like technology.
IZRL Top 10 Holdings
IZRL is essentially a bet on Israel’s innovation engine, with a heavy tilt toward tech and health care names. Software players like Wix and Monday.com have been rising recently but show mixed momentum over the year, suggesting some earlier excitement is losing steam. On the biotech side, Alpha Tau Medical and Urogen Pharma are more volatile passengers, helping when sentiment is upbeat but adding risk when markets turn cautious. Similarweb and Riskified round out the story as data and e-commerce infrastructure plays, keeping the fund firmly anchored in Israel’s high-growth, high-risk tech ecosystem.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Wix | 2.52% | $3.37M | $3.43B | -37.74% | 63 Neutral | |
| Alpha Tau Medical Ltd | 2.05% | $2.75M | $1.35B | 372.15% | 38 Underperform | |
| Pagaya Technologies Ltd | 2.01% | $2.69M | $1.81B | -35.78% | 54 Neutral | |
| Teva Pharmaceutical | 1.91% | $2.56M | $42.99B | 102.28% | 63 Neutral | |
| Urogen Pharma | 1.90% | $2.54M | $2.29B | 141.05% | 50 Neutral | |
| Similarweb | 1.89% | $2.54M | $721.83M | -9.75% | 50 Neutral | |
| Riskified | 1.86% | $2.49M | $779.02M | 28.82% | 51 Neutral | |
| Monday.com | 1.85% | $2.47M | $3.84B | -49.00% | 66 Neutral | |
| Silicom | 1.81% | $2.43M | $250.73M | 183.67% | 57 Neutral | |
| Matrix | 1.81% | $2.42M | ₪8.81B | -17.90% | 66 Neutral |
IZRL Technical Analysis
Negative
―
Price Trends
29.92
Negative
29.96
Negative
29.51
Negative
Market Momentum
-0.25
Positive
42.08
Neutral
11.92
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IZRL, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 29.61, equal to the 50-day MA of 29.92, and equal to the 200-day MA of 29.51, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 42.08 is Neutral, neither overbought nor oversold. The STOCH value of 11.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IZRL.
IZRL Peer Comparison
Comparison Results
Performance Comparison
IZRL
ARK Israel Innovative Technology ETF
29.04
2.42
9.09%
TECB
iShares U.S. Tech Breakthrough Multisector ETF
―
―
―
FDTX
Fidelity Disruptive Technology ETF
―
―
―
BCTK
Baron Technology ETF
―
―
―
LOUP
Innovator Loup Frontier Tech ETF
―
―
―
ITEQ
BlueStar Israel Technology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents